To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0750 | Aspulvinone E |
Natural luciferase inhibitor
More description
|
|
| DCC0749 | Aspterric Acid |
Natural inhibitor of pollen development in Arabidopsis thaliana, also inhibiting dihydroxy-acid dehydratase (DHAD)
More description
|
|
| DCC0748 | Asperphenamate |
Natural antineoplastic agent, targeting cathepsin and inducing autophagy effects in breast cancer cells
More description
|
|
| DCC0747 | Asperlicin D |
Novel cholecystokinin antagonist
More description
|
|
| DCC0746 | asperlicin C |
Novel cholecystokinin antagonist
More description
|
|
| DCC0745 | asperlicin |
Selective antagonist for the cholecystokinin receptor CCKA
More description
|
|
| DCC0744 | Asp9726 |
Novel potent Aspergillus hyphal growth inhibitor
More description
|
|
| DCC0743 | Asp9133 |
Novel long-acting muscarinic antagonist (LAMA), showing more selective inhibition of bronchoconstriction against salivation and more rapid onset of action than tiotropium bromide
More description
|
|
| DCC0742 | Asp-7962 |
Novel tropomyosin-related kinase A (TrkA) inhibitor for the oral treatment of pain due to osteoarthritis of the knee
More description
|
|
| DCC0741 | Asp5854 |
Novel dual A2A/A1 AR antagonist
More description
|
|
| DCC0740 | Asp2397 |
Novel antifungal agent against Aspergillus isolates
More description
|
|
| DCC0739 | Asoprisnil |
Selective progesterone receptor modulator
More description
|
|
| DCC0738 | Asns-in-1 |
Novel slow-onset, tight binding, potent asparagine synthetase (ASNS) inhibitor
More description
|
|
| DCC0737 | Asn06917370 |
Novel potent GPR17 agonist
More description
|
|
| DCC0736 | Asn008 |
Novel Permanently-charged Sodium Channel Blocker, Showing Robust Efficacy, a Rapid Onset and Long Duration of Action
More description
|
|
| DCC0735 | Asm-in-21b |
Novel, Potent, Selective, and Direct Acid Sphingomyelinase (ASM) Inhibitor with Antidepressant Activity
More description
|
|
| DCC0734 | Asm-024 |
Novel modulator of acetylcholine receptor function, promoting the in vitro relaxation of β2-adrenoreceptor desensitized tracheas
More description
|
|
| DCC0733 | Ask1 Inhibitor 32 |
Novel, Potent, Selective, and Brain-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Modulating Brain Inflammation In Vivo
More description
|
|
| DCC0732 | Ascochlorin |
Natural Suppressor of MMP-2-Mediated Migration and Invasion by Targeting FAK and JAK-STAT Signaling Cascades
More description
|
|
| DCC0731 | Asc-082 |
Novel inhibitor of inositol-requiring enzyme 1 (IRE-1), also inhibiting G protein-coupled receptor kinase 6 (GRK6)
More description
|
|
| DCC0730 | Asah1-in-e2 |
Novel angiogenesis inhibitor, directly binding to acid ceramidase 1 (ASAH1)
More description
|
|
| DCC0729 | As-703569 |
Selective inhibitor of aurora kinases (AKs)
More description
|
|
| DCC0728 | As3334034 |
Novel Receptor-interacting Protein Kinase 2 (RIP2) Inhibitor
More description
|
|
| DCC0727 | As2034178 |
Novel GPR40 agonist
More description
|
|
| DCC0726 | As1938909 |
Novel SHIP2 inhibitor, increasing Akt phosphorylation, glucose consumption, and glucose uptake in L6 myotubes, specifically upregulating the GLUT1 gene
More description
|
|
| DCC0725 | As1708727 |
Novel Foxo1 inhibitor, exerting anti-diabetic and anti-hypertriglyceridemic effects by improving blood glucose and triglyceride metabolism at the gene expression level
More description
|
|
| DCC0724 | As1670542 |
Second-generation potent orally-active thrombopoietin (TPO) receptor agonist
More description
|
|
| DCC0723 | as1669058 |
Novel GPR119 agonist, potentiating insulin secretion from rat islets and having potent anti-diabetic effects in ICR and diabetic db/db mice
More description
|
|
| DCC0722 | As1468240 |
Potent factor Xa inhibitor with significant oral anticoagulant activity
More description
|
|
| DCC0721 | As1069562 |
Inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake, significantly restoring decreased insulin-like growth factor 1 and fibroblast growth factor 2 mRNA levels in dorsal root ganglion and spinal cord, respectively
More description
|
|